Table 1 Summary of the top 20 cancer and apoptosis-related gene expression changes in HSC-4 cells following ACA treatment for 1 h and 2 h. Genes were selected based on triplicates with p -values ≤ 0.05; and mean fold changes ≥ 1.50
Gene description | GenBank ID | p-value | Fold change (0 h vs. 1h) | Fold change (0 h vs. 2 h) | NF-kB relation |
|---|---|---|---|---|---|
Tumour protien p53 | AK 125880 | 0.0090 | 2.01 | 1.91 | Activator |
F-box protien 21 | BC034045 | 0.0009 | 1.95 | 1.73 | Ubq.b |
BCL2-associated X (Bax) | AK291076 | 0.0106 | 1.83 | 1.54 | Gene Targeta |
Cyclin G2 | BC032518 | 0.0216 | 1.74 | 1.65 | Indirect Act.c |
Tumour necrosis factor alpha (TNF-α) | BC064689 | 0.0411 | 1.62 | 1.63 | Gene Target |
SMAD 6 | AF035528 | 0.0120 | 1.58 | 1.58 | Ubq. |
Endonuclease G | AK023235 | 0.0459 | 1.55 | 1.52 | Gene Target |
Poly (ADP-ribose) polymerase (PARP) | BC031073 | 0.0432 | 1.54 | 1.56 | Activator |
Caspase 6 (CASP-6) | U20536 | 0.0153 | 1.54 | 1.69 | Indirect Act. |
Cyclin-dependent kinase 2 (CDK-2) | U35146 | 0.0383 | 1.53 | 1.51 | Indirect Act. |
v-fos FBJ murine osteosarcoman viral oncogene | BX647104 | 0.0067 | −8.53 | −8.32 | Activator |
Jun oncogene | BC068522 | 0.0016 | −3.32 | −3.11 | Activator |
Fibroblast growth factor 2 (FBF-2) | J04513 | 0.0361 | −1.84 | −1.65 | Gene Target |
Lymphotoxin beta (LTB) | L11015 | 0.0429 | −1.74 | −1.58 | Gene Target |
Nuclear factor of kappa inhibitor delta (lkB-δ) | AF385434 | 0.0239 | −1.65 | −1.60 | Inhibitor |
Mitogen-activated protien 3-kinase (MAP3K) | BC035576 | 0.0313 | −1.59 | −1.59 | Activator |
Tumour necrosis factor receptor (TNF-R) | AF018253 | 0.0062 | −1.56 | −1.57 | Gene Target |
Tumour protien 73 (p73) | AY040827 | 0.0394 | −1.56 | −1.59 | Indirect Act. |
TNFR-associated death domain (TRADD) | BC004491 | 0.0421 | −1.55 | −1.55 | Activator |
TNF receptor-associated factor 1 (TRAF-1) | AK090468 | 0.039 | −1.52 | −1.55 | Gene Target |